Skip to content
Announcement:
Select Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Blog Post:
Designing Beyond Tolerability Limits: Advancing GB-4362 Into Clinical Development
Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors
Menu
Close
Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors
LinkedIn
X
YouTube
Presentations & Publications
ERS 2025: ePoster
09.28.2025
Download as PDF
